Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.95 DKK | -1.55% |
|
+2.19% | +1.19% |
Jun. 26 | Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application | MT |
Jun. 25 | US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.19% | 5.66B | B- | ||
+24.55% | 74.8B | C+ | ||
-6.59% | 22.92B | C+ | ||
+14.17% | 8.74B | B | ||
-2.89% | 7.94B | C | ||
-33.14% | 6.69B | B- | ||
-4.28% | 4.02B | B- | ||
+12.80% | 3.41B | C | ||
+6.92% | 3.18B | C+ | ||
-13.51% | 3.18B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLUN B Stock
- LUN Stock
- Ratings Lundbeck